Topics:
Thoracic Malignancies • Medical Oncology
Would you consider first line osimertinib to patients with an EGFR Exon 18 G719X mutation?
Are the specific Exon 18 mutations that are more sensitive to TKI?
Answer from: Medical Oncologist at Academic Institution
Yes, I would consider osimertinib. Afatinib is the only EGFR TKI that is FDA-approved for the rare sensitizing EGFR mutations based on pooled data from LUX-Lung 2/3/6. These studies included 18 patients with G719X mutations with a RR 78%, PFS 14 mo., and OS 27 mo. (Yang, et al. Lancet Oncol 2015;16:...
Thank you, @Sandip P. Patel. Started on afatinib a...